| Tofacitinib (n = 161) | Baricitinib (n = 81) | Crude risk ratio (95% CI) | Adjusted risk ratio (95% CI) |
---|---|---|---|---|
DAS28-ESR | ||||
 Remission, n (%) | 29 (18.0) | 20 (24.7) | 0.73 (0.44 to 1.21) | 0.71 (0.44 to 1.18) |
 LDA achievement, n (%) | 51 (31.7) | 37 (45.7) | 0.69 (0.50 to 0.96) | 0.68 (0.49 to 0.95) |
SDAI | ||||
 Remission, n (%) | 34 (21.1) | 22 (27.2) | 0.78 (0.49 to 1.24) | 0.73 (0.46 to 1.16) |
 LDA achievement, n (%) | 103 (64.0) | 50 (61.7) | 1.04 (0.84 to 1.27) | 1.03 (0.85 to 1.24) |
CDAI | ||||
 Remission, n (%) | 29 (18.0) | 18 (22.2) | 0.81 (0.48 to 1.37) | 0.80 (0.47 to 1.37) |
 LDA achievement, n (%) | 106 (65.8) | 49 (60.5) | 1.09 (0.88 to 1.34) | 1.11 (0.91 to 1.35) |